KYRA

Post-LOE

drospirenone; ethinyl estradiol

Fosun Pharma

ANDAORALTABLET

Approved

Jul 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

KYRA (drospirenone; ethinyl estradiol) by Fosun Pharma is ovulation. Approved for pregnancy. First approved in 2019.

Drug data last refreshed 18h ago

Mechanism of Action

ovulation.

Indications (1)

pregnancy

Clinical Trials (2)

NCT03691415N/ATerminated

Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea

Started Sep 2018

71 enrolled

Submental Fullness

NCT03425253Phase 4Completed

Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour

Started Feb 2018

58 enrolled

Contour

Company

Worked on KYRA at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.